 (Gut 1996; 38: 90-98) 
normal colon sections examined using the antisense probe (Fig la) . Examination of the five ulcerative colitis and six Crohn's disease tissues with the antisense probe consistently showed abundant mRNA for IL8 in cells morphologically and phenotypically (CD68 positivedata not shown) resembling macrophages in proximity to ulcerated epithelium, as well as in many neutrophils in lamina propria, ulcer slough, and crypt abscesses. IL8 expression was found predominantly in areas below and adjacent to active ulceration, but isolated IL8 expressing cells also were apparent in inflamed mucosa displaying intact epithelium (Fig lb) and in a perivascular distribution (Fig Id) . In situ hybridisation using the sense probe for IL8 was repeatedly negative in all tissues examined (Fig ic and e) . There was no demonstrable IL8 mRNA in epithelial cells, either adjacent to or away from areas of ulceration in IBD tissues (Fig ib) , nor was IL8 expressed in normal colon epithelial cells (Fig la) .
In three experiments serial sections stained with the anti-CD 14 antibody, CMRF3 1, showed that many of the IL8 mRNA expressing macrophages also seemed to express the monocyte marker CD1 4, suggesting their recent arrival from the circulation as previously described2' (Fig 2a and b) . 
IL8 immunohistochemistry
Staining of PLP fixed and formalin fixed tissues with the polyclonal antibody against IL8 showed a pattern of IL8 production similar to that seen for mRNA expression with in situ hybridisation. Negligible IL8 staining was seen in tissue from normal colons (Fig 3a) . Macrophages, identified in serial sections by their CD68 positivity, and neutrophils associated with ulceration in all seven ulcerative colitis and 11 Crohn's disease specimens were strongly positive for IL8, as were neutrophils in crypt abscesses (Fig 3c and e) . Little IL8 staining was seen away from active epithelial ulceration. Tissue incubated using anti-IL8 pre-adsorbed with recombinant human IL8 was negative in all sections examined (Fig 3b, d, and f) . As (Fig 4a) . To control for contaminating T lymphocytes in the isolated macrophage populations, T cells isolated from both normal and inflamed colon also were probed but no IL8 mRNA expression was detected (Fig 4a) .
When a model of the recently recruited mucosal macrophage, the lipopolysaccharide treated monocyte, was treated with agents used in the treatment of IBD, IL8 expression was changed. Exposure to hydrocortisone resulted in reduced IL8 mRNA values, although the decrease was less noticeable than that seen for cyclosporin A. In addition, 5-aminosalicylic acid reduced IL8 mRNA expression in lipopolysaccharide treated monocytes, both in the absence and in the presence of hydrocortisone (Fig 4b) .
IL8 secretion by isolated intestinal macrophages and by peripheral blood monocytes Macrophages isolated from uninflamed colon cancer bearing resections produced low concentrations of IL8 protein, which were not augmented by stimulation using lipopolysaccharide (Fig 5) . Macrophages from IBD affected colons produced significantly greater quantities of IL8 than those from uninflamed colons (p<0 005), and this secretion was significantly increased by stimulation using lipopolysaccharide (p=0 01; Fig 5) . There was no difference between ulcerative colitis and Crohn's disease in the quantity of IL8 generated (data not shown).
To ensure that the observed changes of IL8 mRNA expression in lipopolysaccharide stimulated monocytes were reflected in IL8 protein production, peripheral blood monocytes were stimulated for six hours using lipopolysaccharide. Hydrocortisone, 5-aminosalicylic acid, hydrocortisone plus 5-aminosalicylic acid, and cyclosporin A all produced significant decreases in the quantities of IL8 secreted by lipopolysaccharide stimulated cells (Fig 6) .
Discussion
This study confirms and extends earlier studies8 29 30 bv showing the cell types involved in IL8 protein production as well as mRNA expression in the mucosa of active IBD. Recently there has been increasing evidence for an active role for neutrophils as mediators in inflammatory reactions, including the production of IL 1 ,B, IL 6, GM-CSF, tumour necrosis factor (TNF) ox, and IL 1 receptor antagonist,3 Significantly, IL8 expression is confined largely to areas of ulceration or those closely adjacent; inflamed mucosa displaying intact epithelium shows little IL8 production. This finding may relate to the quantity of lipopolysaccharide and other bacterial products that have ready access to lamina propria cells in regions where the epithelial barrier is disrupted, resulting in the stimulation of proinflammatory and chemotactic cytokine production thereby attracting further inflammatory cells into the mucosal lesion. The subsequent destructive effects of newly arrived neutrophils may extend the ulceration increasing exposure of the lamina propria to lipopolysaccharide in a positive feedback loop.
We show also that the isolated intestinal macrophage mirrors the in vivo expression of IL8 in IBD. Compared with those from normal colon, significantly greater numbers of IBD mucosal macrophage preparations express IL8 mRNA. Similarly, macrophages isolated from IBD affected mucosa produce greater quantities of IL8 protein than macrophages from uninflamed colon cancer bearing mucosa and while the latter cells seem not to produce more IL8 after stimulation using lipopolysaccharide, IBD macrophages respond to lipopolysaccharide by a significant increase in IL8 secretion. This is an important finding and provides a functional correlate for our finding that IBD macrophages, but not macrophages in normal colon, strongly express CD14. 32 Although it has been shown previously that corticosteroids35 and cyclosporin A36 may inhibit IL8 production we have shown also that 5-aminosalicylic acid down regulates the expression and production of IL8 in a model of the recently recruited intestinal macrophage, the lipopolysaccharide stimulated, CD14 positive blood monocyte. These data provide a further insight into the mechanisms of action of the agents used in the treatment of IBD, and suggests that they work, at least in part, by reducing the attraction of a fresh population of neutrophils to inflamed mucosa. An important finding from this study is the absence of detectable IL8 production by epithelial cells in both normal and inflamed colon. Epithelial cell IL8 production has been suggested by the finding that some, although not all, lipopolysaccharide stimulated colon cancer cell lines produce appreciable quantities of IL8.1618 37 38 One of these studies'8 has suggested also that epithelial cell crypts isolated from normal colons produce IL8, but the crypt cell population may have been contaminated by subepithelial macrophages, as the marker used to exclude macrophage contamination was CD14, which is not seen on normal colonic macrophages.32 Indeed we also have been able to show IL8 production by isolated colonic crypts, but immunohistochemical analysis of these crypt preparations shows significant contamination by nonepithelial cells, especially macrophages (unpublished findings). Moreover the finding of IL8 secretion by isolated crypt epithelial cells may be an artefact. A recent preliminary report suggests that the process of isolating crypt epithelial cells from human intestine strongly induces IL8 transcription during the first hours of culture in vitro.39 Ignoring these caveats and given the sensitivity of riboprobe generated in situ hybridisation,31 if epithelial cells do produce IL8 in IBD mucosa it is probably in quantities insufficient to add significantly to the amount expressed by macrophages and neutrophils.
This study has shown a link between the analysis of cell populations isolated from resected colons and the determination of cytokine profiles in the tissue using in situ hybridisation and immunohistochemistry. Work now in progress is aimed at elucidating some of the signals responsible for the attraction of other inflammatory cells to IBD affected mucosa; combined with this study it offers the potential for future treatment directed at blocking the recruitment of leucocytes in IBD.
